/ /

  • linkedin
  • Increase Font
  • Sharebar

    Neuroprotective strategy primed for progress

    CNTF-secreting device has positive results in phase I study

    Advancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.

    “There has been a real reticence to engage in development programs for neuroprotective interventions because of the long timeline necessary to bring a product to market,” said Dr. Goldberg, professor and chair, Byers Eye Institute, Stanford University, Palo Alto, CA. 


     

    “Many researchers . . . have identified treatments that could maintain the viability of retinal ganglion cells (RGCs) or even augment or enhance the function of residual RGCs, and the threshold has been lowered to bring these modalities into clinical testing,” he said.

    Clinical trial update

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results